News

A meta-analysis shows the experimental therapy has favorable benefits for certain aspects of pain, as well as preferrable avenues of administration.

An increased morbidity risk has been found to be associated with central sleep apnea in infants with congenital heart disease by University of Arizona investigators.

A placebo-controlled study of daily low-dose aspirin found that treatment did not prolong healthy living in older adults. In fact, aspirin use was associated with increased risk of major hemorrhage.

Switching to the smallest complete daily pill for HIV from other regimens with different components of the same drug classes proved advantageous for patients with HIV, treating the infection with less adverse effects.

Symptoms of cardiovascular disease, including intima-media thickness and coronary artery calcium, were more common in patients with HIV and cytomegalovirus.

The FDA has granted a rare pediatric disease designation to Lin BioScience’s LBS-008 for the treatment of Stargardt disease.

A quarter of surveyed second-year residents reported high emotional exhaustion and depersonalization. Nearly half reported weekly symptoms of burnout.

A new statement from the US Preventive Services Task Force emphasizes the need for behavior-based interventions to help adults with obesity lose weight and maintain lower weight.

The FDA has granted an orphan drug designation to Cytori Therapeutics’ ATI-1123 chemotherapy drug for the treatment of small cell lung cancer.

Continuous positive airway pressure was previously defined as the primary treatment of OSA, as well as related issues like mask fits. Weight management has been continuously unaddressed in guidelines and literature.

Evidence from a number of countries suggests that America’s expansion of opioid addiction treatment programs will pay dividends in curbing rates of HIV transmission among people who inject drugs.

The study results may help enable the development of nasal microbial markers of asthma for detection and disease monitoring.

Cure CMD (Congenital Muscular Dystrophy) is pleased to announce the recipient of a grant co-funded with Muscular Dystrophy UK: Dr. Giséle Bonne at the INSERM-Myology Institute in Paris.

Bridge the Gap – SYNGAP Education and Research Foundation presented Texas Children’s Hospital with their first research grant of $25,000.

In results reported at the European Academy of Dermatology and Venereology Congress, two-week and four-week doses of the subcutaneous drug proved efficacious in improving patient skin.

The FDA has granted a fast track designation to miransertib for the treatment of PIK3CA-Related Overgrowth Spectrum, a group of ultra-rare genetic disorders.

The patient population tends to have a more unbalanced immune profile to that of European American patients, indicating a potential for tailored treatment options to combat inflammation.

Almost 20% of young people with autism spectrum disorder (ASD) also were diagnosed with depression in a study that tracked participants into their 20s.

A new study is the first to identify eosinophil counts as a predictor of outcomes in human patients.

Physicians are primarily delivering disease management, rather than healing and care. The current system is a placing a strain on the practice.

Investigators reported an overall mean estimation error ranging from 3.47% to 5.29% in five-year outcomes for patients with AMD.

Stay up-to-date on the latest rare disease news by checking out our top 5 articles of the week.

BioLyte Laboratories is voluntarily recalling lots of their topical gel at risk of possible microbial contamination can result in increased infections that may require medical intervention and could be potentially life threatening to certain individuals.

The FDA approved the Teva Pharmaceutical drug, just months after its phase 3 program for headache clusters was discontinued.

The National Institutes of Health has launched the Cure Sickle Cell Initiative to accelerate the pace at which genetic-based curative therapies are developed for sickle cell disease.

The device is a balloon catheter designed to treat rare, but life-threatening perforations in the coronary artery, which can occur during Percutaneous Coronary Intervention procedures.

The FDA has approved a device intended for the treatment of acute coronary heart perforation, a rare, but potentially life-threatening complication of heart vessel procedures.

Investigators found that active choice intervention correlated with a nearly 10% increased likelihood of patients receiving the seasonal flu vaccine.

Patients with asthma and eosinophilia have thicker airway nerves, according to new research.

Addressing housing arrangements during a medical visit may be as important as addressing blood pressure or blood sugar levels.